Adapted physical activity for recovery after stem cell transplantation
Official title: APALLO : Post Allogeneic Stem Cell Transplantation Adapted Physical Activity for Patient With Hematological Malignancies
Run by Centre Hospitalier Universitaire de Nice · NCT05379738 · Data updated 2026-11-12
This study tests if doing six sessions of adapted physical activity at home can help people recovering from stem cell transplants lose weight and improve their quality of life.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 75 (estimated) |
| Sponsor | Centre Hospitalier Universitaire de Nice Academic / other |
| Locations | 1 site (Nice) |
| Status | Recruiting |
| Started | June 10, 2022 |
| Main results expected | December 10, 2026 |
| Study ends | April 10, 2028 |
| Registry record updated | January 30, 2024 |
| Trial ID | NCT05379738 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 or older who are scheduled for allogeneic stem cell transplantation and can provide informed consent.
✕Probably not a fit
Patients with significant additional physical or mental diseases, or those who develop incapacity to engage in physical activity, may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the effects of six sessions of adapted physical activity on patients recovering from allogeneic stem cell transplantation for hematological malignancies. Participants will engage in these sessions at home between one and three months post-transplant. The primary focus is to assess improvements in weight loss and quality of life resulting from this tailored physical activity program.
Why it matters
Potential benefit: If successful, this approach could enhance recovery and overall quality of life for patients undergoing stem cell transplantation.
How similar studies have gone: While similar approaches have been explored, this specific adaptation for post-stem cell transplantation recovery is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion criteria : * Patient aged 18 or more * Patient with social security * Patient who accept the study and sign the consent form * Patient programmed for an allogenic stem cell transplantation Non inclusion criteria : * Patients with a guardianship * Patients with a significant additional physic or mental disease Exclusion criteria * Patients who did not receive an allogeniac stem cell transplantation * Patients still hospitalized between day 30 and day 100 after stem cell transplantation * Patients who finally refuses the study * Patients who develop a physical or mental incapacity to practice physical activity
Where it's running
-
CHU NICE, hopital ARCHET 1, hématologie
Nice, France Recruiting
Study contacts
- Principal investigator: SOLDATI Alizée — CHU NICE, hopital ARCHET 1, hématologie
- Study coordinator: SOLDATI Alizée
- Email: soldati.a@chu-nice.fr
- Phone: 04 92 03 96 27
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Dabrafenib and trametinib for rare cancers with BRAF V600 mutations
This arm tests whether dabrafenib and trametinib can help adults, children, and teens with cancers that have a BRAF V600 mutation.
-
Capmatinib treatment for adults with cancers having MET gene changes
This study is testing if capmatinib, a drug for lung cancer, can help adults with different types of cancers that have changes in the MET gene.
-
Home management program for patients with blood cancers after chemotherapy
This study tests a new home care program for patients with blood cancers after high-dose chemotherapy to see if it helps them recover better while allowing them to leave the hospital sooner.
-
Pharmacogenomics to improve voriconazole dosing for fungal infections
This trial will test whether using a patient's CYP2C19 genotype with Bayesian dosing software helps get voriconazole levels into the therapeutic range by Day 8 for people with fungal infections, including those with blood cancers.
-
Combination of trastuzumab and pertuzumab for treating cancers with HER2 mutations
This study is testing if a combination of two cancer drugs, trastuzumab and pertuzumab, can help adults and young people with cancers that have HER2 mutations or amplifications.
-
Entrectinib treatment for patients with ROS1-positive cancers
This study is testing if the drug entrectinib can help people with different types of cancers that have a ROS1 gene fusion, including adults and kids, to see if it works better than what’s currently available.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.